Animal models of scleroderma: From cellular and molecular mechanisms to novel antifibrotic strategies

Advances in Vascular Medicine

Volumn , Issue , 2010, Pages 57-75

  Manetti, Mirko ^a,b   Neumann, Elena ^b   Distler, Oliver ^c   Müller Ladner, Ulf ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891963686     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84882-637-3_3     Document Type: Chapter

References (91)

1. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-205.
2. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med. 2004;140:37-50.
3. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557-567.
4. Distler JH, Jüngel A, Caretto D, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum. 2006;54:214-225.
5. Wynn TA. Fibrotic disease and the T (H) 1/T (H) 2 paradigm. Nat Rev Immunol. 2004;4:583-594.
6. Ishida W, Mori Y, Lakos G, et al. Intracellular TGF-b receptor blockade abrogates Smad-dependent fibroblast activation in vitro and in vivo. J Invest Dermatol. 2006;126:1733-1744.
7. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum. 2003;48:1964-1978.
8. Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: a model of scleroderma. Arthritis Rheum. 2006;54:3011-3021.
9. Shi-Wen X, Rodriguez-Pascual F, Lamas S, et al. Constitutive ALK5-independent c-Jun. N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol. 2006;26:5518-5527.
10. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54:2271-2279.
11. Huber LC, Distler J H W, Moritz F, et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 2007;56:2755-2764.
12. Clark SH. Animal models in scleroderma. Curr Rheumatol Rep. 2005;7:150-155.
13. Samuel CS, Zhao C, Yang Q, et al. The relaxin knockout mouse: a model of progressive scleroderma. J Invest Dermatol. 2005;125:692-699.
14. Denton CP, Lindahl GE, Khan K, et al. Activation of key profibrotic mechanisms in transgenic fibroblasts expressing kinase-deficient type II transforming growth factor-b receptor (TbRIIDk). J Biol Chem. 2005;280:16053-16065.
15. Sonnylal S, Denton CP, Zheng B, et al. Postnatal induction of transforming growth factor b signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum. 2007;56:334-344.
16. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26:587-595.
17. Yamamoto T, Takagawa S, Katayama I, et al. Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol. 1999;112:456-462.
18. Yamamoto T. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis? Arch Dermatol Res. 2006;297:333-344.
19. Sambo P, Baroni SS, Luchetti M, et al. Oxidative stress in scleroderma: maintenance of sclerodermia fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001;44:1667-1676.
20. Azuma A, Takahashi S, Nose M, et al. Role of E-selectin in bleomycin induced lung fibrosis in mice. Thorax. 2000;55:147-152.
21. Yamamoto T, Nishioka K. Possible role of apoptosis in the pathogenesis of bleomycininduced scleroderma. J Invest Dermatol. 2004;122:44-50.
22. Yamamoto T, Tokozeki H, Nishioka K. Fas- and FasL-deficient mice are resistant to the induction of bleomycin-induced scleroderma. Arch Dermatol Res. 2007;298:465-468.
23. Oi M, Yamamoto T, Nishioka K. Increased expression of TGF-beta1 in the sclerotic skin in bleomycin-"susceptible" mouse strains. J Med Dent Sci. 2004;51:7-17.
24. Yamamoto T, Nishioka K. Animal model of sclerotic skin. V: increased expression of alphasmooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol. 2002;102:77-83.
25. Matsushita M, Yamamoto T, Nishioka K. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol. 2005;139:429-438.
26. Takagawa S, Lakos G, Mori Y, Yamamoto T, Nishioka K, Varga J. Sustained activation of transforming growth factor-b/mediated signalling in a murine model of scleroderma. J Invest Dermatol. 2003;121:41-50.
27. Lakos G, Takagawa S, Chen SJ, et al. Targeted disruption of TGF-b/smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol. 2004;165:203-217.
28. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol. 2003;121:510-516.
29. Ferreira AM, Takagawa S, Fresco R, Zhu X, Varga J, DiPietro LA. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol. 2006;126:1900-1908.
30. Matsushita M, Yamamoto T, Nishioka K. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol. 2004;135:348-356.
31. Belperio JA, Dy M, Burdick MD, et al. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2002;27:419-427.
32. Lee CG, Homer RJ, Zhu Z, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor b1. J Exp Med. 2001;194:809-821.
33. Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA. 2007;104:2827-2830.
34. Kaviratne M, Hesse M, Leusink M, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol. 2004;173:4020-4029.
35. Helene M, Lake-Bullock V, Zhu J, Hao H, Cohen DA, Kaplan AM. T cell independence of bleomycin-induced pulmonary fibrosis. J Leukoc Biol. 1999;65:187-195.
36. Yamamoto T, Nishioka K. Animal model of sclerotic skin. IV. Induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol. 2001;117:999-1001.
37. Yamamoto T, Nishioka K. Animal model of sclerotic skin. VI. Evaluation of bleomycininduced skin sclerosis in nude mice. Arch Dermatol Res. 2004;295:453-456.
38. Santiago B, Gutierrez-Canas I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol. 2005;125:450-455.
39. Wu M-H, Yokozeki H, Takagawa S, et al. Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma. Gene Ther. 2004;11:170-180.
40. Ulloa L, Doody J, Massagué J. Inhibition of transforming growth factor-b/SMAD signaling by the interferon-g/STAT pathway. Nature. 1999;397:710-713.
41. Hunzelmann N, Anders S, Fierlbeck G, et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol. 1997;36:433-435.
42. Kimura M, Kawahito Y, Hamaguchi M, et al. SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice. Biomed Pharmacother. 2007;61:222-228.
43. Chan ES, Fernandez P, Merchant AA, et al. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. 2006;54:2632-2642.
44. Distler JH, Jüngel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. 2007;56:311-322.
45. Jaffee BD, Claman HN. Chronic graft-versus-host disease (GvHD) as a model for scleroderma. Cell Immunol. 1983;77:1-12.
46. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-b treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999;163:5693-5699.
47. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graftversus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168:3088-3098.
48. Zhang Y, McCormick LL, Gilliam AC. Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2003;121:713-719.
49. Zhou L, Askew D, Wu C, Gilliam AC. Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol. 2007;127:281-292.
50. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD. A modified model of graft-versushost-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum. 2004;50:1319-1331.
51. Siracusa LD, McGrath R, Ma Q, et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res. 1996;6:300-313.
52. Green MC, Sweet HO, Bunker LE. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol. 1976;82:493-512.
53. Pablos JL, Everett ET, Norris JS. The tight skin mouse: an animal model of systemic sclerosis. Clin Exp Rheumatol. 2004;22:S81-S85.
54. Baxter RM, Crowell TP, McCrann ME, Frew EM, Gardner H. Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents. Lab Invest. 2005;85:1199-1209.
55. Saito S, Kasturi K, Bona C. Genetic and immunologic features associated with sclerodermalike syndrome of TSK mice. Curr Rheumatol Rep. 1999;1:34-37.
56. Wallis DD, Tan FK, Kessler R, et al. Fibrillin 1 abnormalities in dermal fibroblast cultures from first degree relatives of patients with systemic sclerosis (scleroderma). Arthritis Rheum. 2004;50:329-331.
57. Tan FK, Stivers DN, Foster MW, et al. Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum. 1998;41:1729-1737.
58. Fleischmajer R, Jacobs L, Schwartz E, Sakai LY. Extracellular microfibrils are increased in localized and systemic scleroderma skin. Lab Invest. 1991;64:791-798.
59. Tan FK, Arnett FC, Antohi S, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol. 1999;163:1066-1072.
60. Saito S, Nishimura H, Brumeanu TD, et al. Characterization of mutated protein encoded by partially duplicated fibrillin-1 gene in tight skin (TSK) mice. Mol Immunol. 1999;36:169-176.
61. Lemaire R, Farina G, Kissin E, et al. Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen. Arthritis Rheum. 2004;50:915-926.
62. Isogai Z, Ono RN, Ushiro S, et al. Latent transforming growth factor b-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem. 2003;278:2750-2757.
63. Denton CP, Zheng B, Shiwen X, et al. Activation of a fibroblast specific enhancer of the Proa2 (I) collagen gene in tight-skin mice. Arthritis Rheum. 2001;44:712-722.
64. McGaha TL, Le M, Kodera T, et al. Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum. 2003;48:2275-2284.
65. McGaha TL, Saito S, Phelps RG, et al. Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol. 2001;116:136-143.
66. Kodera T, McGaha TL, Phelps R, Paul WE, Bona CA. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-b production by fibroblasts. Proc Natl Acad Sci USA. 2002;99:3800-3805.
67. Wallace VA, Kondo S, Kono T, et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol. 1994;24:1463-1466.
68. Siracusa LD, McGrath R, Fisher JK, Jimenez SA. The mouse tight skin (Tsk) phenotype is not dependent on the presence of mature T and B lymphocytes. Mamm Genome. 1998;9:907-909.
69. Dodig TD, Mack KT, Cassarino DF, Clark SH. Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum. 2001;44:723-727.
70. Ong D, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol. 1998;128:2619-2629.
71. Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum. 2002;46:1689-1690.
72. Levi-Schaffer F, Nagler A, Slavin S, Knopov V, Pines M. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice. Effect of halofuginone. J Invest Dermatol. 1996;106:84-88.
73. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor- b-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002;118:461-470.
74. Iwasaki T, Imado T, Kitano S, Sano H. Hepatocyte growth factor ameliorates dermal sclerosis in the tight-skin mouse model of scleroderma. Arthritis Res Ther. 2006;8:R161.
75. Ong VH, Evans LA, Shiwen X, et al. Monocyte chemoattractant protein 3 as a mediator of fibrosis. Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum. 2003;48:1979-1991.
76. Saito E, Fujimoto M, Hasegawa M, et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002;109:1453-1462.
77. Tedder TF, Poe JC, Fujimoto M, Haas KM, Sato S. The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system. Curr Dir Autoimm. 2005;8:55-90.
78. Asano N, Fujimoto M, Yazawa N, et al. B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol. 2004;165:641-650.
79. Hasegawa M, Hamaguchi Y, Yanaba K, et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006;169:954-966.
80. Komura K, Manabu F, Yanaba K, et al. Blockade of CD40-CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Ann Rheum Dis. 2008; doi: 10.1136/ard.2007.073387.
81. Matsushita T, Fujimoto M, Hasegawa M, et al. BAFF antagonist attenuates the development of skin fibrosis in tight-skin mice. J Invest Dermatol. 2007;127:2772-2780.
82. Christner PJ, Peters J, Hawkins D, Siracusa LD, Jimenez SA. The tight skin 2 mouse. An animal model of scleroderma displaying cutaneous fibrosis and mononuclear cell infiltration. Arthritis Rheum. 1995;38:1791-1798.
83. Christner PJ, Yufit T, Peters J, McGrath R, Conway RF, Jimenez SA. Transcriptional activation of a1 (III) procollagen gene in Tsk2/+ dermal fibroblasts. Biochem Biophys Res Commun. 2003;303:406-412.
84. Gentiletti J, McCloskey L, Artlett CM, Peters J, Jimenez SA, Christner PJ. Demonstration of autoimmunity in the tight skin-2 mouse: a model for scleroderma. J Immunol. 2005;175:2418-2426.
85. Le Hir M, Martin M, Haas C. A syndrome resembling human systemic sclerosis (scleroderma) in MRL/lpr mice lacking interferon-gamma (IFNg) receptor (MRL/lprgR-/-). Clin Exp Immunol. 1999;115:281-287.
86. Gershwin ME, Abplanalp H, Castles JJ, et al. Characterization of a spontaneous disease of white leghorn chickens resembling progressive systemic sclerosis (scleroderma). J Exp Med. 1981;153:1640-1659.
87. Sgonc R. The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol. 1999;120:169-176.
88. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996;98:785-792.
89. Sgonc R, Gruschwitz MS, Boeck G, Sepp N, Gruber J, Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000;43:2550-2562.
90. Worda M, Sgonc R, Dietrich H, et al. In vivo analysis of the apoptosis-inducing effect of antiendothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay. Arthritis Rheum. 2003;48:2605-2614.
91. Nguyen VA, Sgonc R, Dietrich H, Wick G. Endothelial injury in internal organs of University of California at Davis line 200 (UCD 200) chickens, an animal model for systemic sclerosis (scleroderma). J Autoimmun. 2000;14:143-149.